Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA259651 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Targeting the MLL complex in castration-resistant prostate cancer [ChIP-seq]
| PRJNA259656 | ENA
Project description:Resistance to androgen deprivation therapies and increased androgen receptor (AR) activity are major drivers of castration-resistant prostate cancer (CRPC). Prior work has focused on targeting AR directly; however, the identification and targeting of co-activators of AR signaling remains an underexplored area. Here we demonstrate that the MLL (mixed-lineage leukemia) complex, a well-known contributor in MLL-fusion-positive leukemia, acts as a co-activator of AR signaling. AR interacts with the MLL complex via its subunit, menin. Small molecule inhibition of the menin-MLL interaction blocks AR signaling and inhibits tumor growth in vivo. Furthermore, we find that menin is up-regulated in CRPC and high expression correlates with poor overall survival. Our study identifies the MLL complex as a co-activator of AR that can be targeted in advanced prostate cancer. ASH2L / Menin / MLL1 were knocked down using shRNA /siRNA in two prostate cancer cell lines, VCaP and LNCaP.
2015-03-02 | E-GEOD-60836 | biostudies-arrayexpress
Project description:Resistance to androgen deprivation therapies and increased androgen receptor (AR) activity are major drivers of castration-resistant prostate cancer (CRPC). Prior work has focused on targeting AR directly; however, the identification and targeting of co-activators of AR signaling remains an underexplored area. Here we demonstrate that the MLL (mixed-lineage leukemia) complex, a well-known contributor in MLL-fusion-positive leukemia, acts as a co-activator of AR signaling. AR interacts with the MLL complex via its subunit, menin. Small molecule inhibition of the menin-MLL interaction blocks AR signaling and inhibits tumor growth in vivo. Furthermore, we find that menin is up-regulated in CRPC and high expression correlates with poor overall survival. Our study identifies the MLL complex as a co-activator of AR that can be targeted in advanced prostate cancer.
2015-03-02 | GSE60836 | GEO
Project description:microRNA expression profile of castration-resistant prostate cancer
| PRJDB5095 | ENA
Project description:Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer (microarray)
| PRJNA238360 | ENA
Project description:Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer (ChIP-Seq)
| PRJNA238361 | ENA
Project description:Expression data for primary localized prostate cancer versus castration-resistant bone metastatic prostate cancer
| PRJNA147325 | ENA
Project description:Gene Expression analysis of castration-resistant prostate cancer bone metastases
| PRJNA141237 | ENA